Subscribe To Our Free Newsletter |
Biocon surges after signing exclusive licensing deal for Liraglutide with Handok
Biocon jumped 4.19% to Rs 328.55 after the company announced the signing of an exclusive licensing and supply agreement with South Korea-based Handok for the commercialization of its vertically integrated & complex drug product Synthetic Liraglutide.